Sector
PharmaceuticalsCMP
as on 03 Jul, 2024 12:00:00 AM
Open
₹107.2Prev. Close
₹107.1Turnover(Lac.)
₹54.62Day's High
₹108Day's Low
₹106.7752 Week's High
₹144.352 Week's Low
₹97.9Book Value
₹26Face Value
₹10Mkt Cap (₹ Cr.)
384.52P/E
0EPS
0Divi. Yield
010 Jul 2023
12:00 AM
AGM
Announcement Date: 10 Jul, 2023
10 Jul 2023
12:00 AM
BookCloser
10 May 2024
12:00 AM
Board Meeting
Agenda : Audited Result
18 Jan 2024
12:00 AM
EGM
| Y/e 31 Mar( In .Cr) | Mar-2023 | Mar-2022 | Mar-2021 | Mar-2020 |
|---|---|---|---|---|
Equity Capital | 48.13 | 28.69 | 28.69 | 28.69 |
Preference Capital | 1.08 | 0.78 | 0.71 | 0.64 |
Reserves | 28.3 | 15.75 | -24.28 | -9.91 |
Net Worth | 77.51 | 45.22 | 5.12 | 19.42 |
Minority Interest |
| Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
|---|---|---|---|---|
Revenue | 164.34 | 62.26 | 33.67 | 41.68 |
yoy growth (%) | 163.95 | 84.92 | -19.21 | -46.56 |
Raw materials | -30.86 | -23.52 | -15.48 | -21.53 |
As % of sales | 18.77 | 37.77 | 45.99 | 51.66 |
Employee costs | -16.21 | -13.02 | -10.57 | -10.89 |
| Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
|---|---|---|---|---|
Profit before tax | 64.9 | -16.96 | -24.24 | -12.69 |
Depreciation | -15.38 | -8.04 | -5.64 | -6.3 |
Tax paid | -20.33 | 3.93 | -1.19 | 0.38 |
Working capital | 29.28 | 5.11 | -23.18 | 16.67 |
Other operating items |
| Y/e 31 Mar | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
|---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 163.95 | 84.92 | -19.21 | -46.56 |
Op profit growth | 575.87 | -742.93 | 333.98 | -102.37 |
EBIT growth | 887.98 | -262.21 | 7.28 | -127.49 |
Net profit growth | -375.97 | -72.81 | 390.71 | 5,718.25 |
| Particulars (Rupees in Crores.) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 | Mar-2020 |
|---|---|---|---|---|---|
Gross Sales | 111.19 | 93.07 | 194.08 | 86.25 | 61.49 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 111.19 | 93.07 | 194.08 | 86.25 | 61.49 |
Other Operating Income | 0 | 0 | 0 | 0 | 0 |
Other Income | 1.45 | 3.4 | 2.09 | 1.56 | 3.09 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
|---|---|---|---|---|---|---|---|
Sun Pharmaceuticals Industries Ltd SUNPHARMA | 1,522.65 | 120.29 | 3,65,682.64 | 867.6 | 0.89 | 5,536.99 | 98.75 |
Divis Laboratories Ltd DIVISLAB | 4,557.05 | 76.97 | 1,21,312.5 | 531 | 0.66 | 2,259 | 507.93 |
Cipla Ltd CIPLA | 1,477.7 | 32.36 | 1,20,195.02 | 1,038.4 | 0.57 | 3,444.92 | 346.41 |
Zydus Lifesciences Ltd ZYDUSLIFE | 1,098.85 | 31.35 | 1,08,114.81 | 1,405.2 | 0.28 | 3,172.6 | 156.19 |
Dr Reddys Laboratories Ltd DRREDDY | 6,484 | 24.48 | 1,06,298.05 | 1,034.8 | 0.63 | 5,081.8 | 1,453.02 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Chairman & MD & CEO
KUNAL NARENDRA GANDHI
Non-Exec. & Independent Dir.
Sandeep P Parikh
Executive Director & CFO
Yogesh B Shah
Non-Exec. & Independent Dir.
Dhara P. Shah
Company Sec. & Compli. Officer
Kishore P Shah
Independent Director
Babulal Jain
Director
Prashant Godha
Director
Shashil Mendonsa
Tel: -
Website: -
Email: -
Tel: -
Website: -
Email: -
Reports by Lyka Labs Ltd
Summary
Initially manufacturing formulations, Lyka Labs brought bulk drugs into its operational fold by amalgamating Lyphin Chemicals Pvt Ltd with itself in Apr. 83. It also added a range of ayurvedic and animal health care products over the years. In 1990, it diversified into marketing medical and diagnostic equipment and instruments of Bekton Dickinson, US; Airsep Corporation, US; Coloplast, Denmark; and Terumo Corporation, Japan. Lyka Exports is the subsidiary of the company. The company offers a broad range of antibiotics used as life-savers and to treat minor infections. It has a fairly widespread product base with tropical steroids for skin disorders, anti-cancer products, cardio-vascular drugs and anti-inflammatory products. Lyka introduced, in India, cough lozenges containing dextromethorphan hydrobromide (DMR), favoured internationally as an effective and safe cough suppressant. Lyka has two formulations division and a bulk drugs division. It also set up additional manufacturing facilities for ointments. As part of its diversification, it has invested in Relic Finance, a company carrying on the business of finance and merchant banking.A GOI-recognised Export House, it received the Certificate of Merit for its excellent export performance in 1993-94. In the same year, it received an award from CHEMEXCIL for its outstanding performance.During 1997-98, the companys administrative office & plant at tarapur has been awarded ISO 9002 certification for its quality management system
Read More
What is the Lyka Labs Ltd share price today?
The Lyka Labs Ltd shares price on nse is Rs.₹107.74 today.
What is the Market Cap of Lyka Labs Ltd?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Lyka Labs Ltd is ₹384.52 Cr. as of 03 Jul ‘24
What is the PE and PB ratio of Lyka Labs Ltd?
The PE and PB ratios of Lyka Labs Ltd is 0 and 3.78 as of 03 Jul ‘24
What is the 52 Week High and Low of Lyka Labs Ltd?
The 52-week high/low is the highest and lowest price at which a Lyka Labs Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Lyka Labs Ltd is ₹97.9 and ₹144.3 as of 03 Jul ‘24
What is the CAGR of Lyka Labs Ltd?
Lyka Labs Ltd's CAGR for 5 Years at 36.38%, 3 Years at 20.84%, 1 Year at -3.82%, 6 Month at -13.49%, 3 Month at -4.88% and 1 Month at 0.42%.
What is the shareholding pattern of Lyka Labs Ltd?
The shareholding pattern of Lyka Labs Ltd is as follows:
Promoters - 58.10 %
Institutions - 0.98 %
Public - 40.92 %
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Securities Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2024, IIFL Securities Ltd. All Rights Reserved
www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.
Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
